Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOVIPA
2023-510004-49-00Phase 2Authorised
- Sponsor
- Hôpital Foch
- Start
- Aug 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dostarlimab, cholecalciferol, oxaliplatin, folinic acid, irinotecan and 1 more in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PDAC), sponsored by Hôpital Foch. Primary endpoint: Objective Response Rate. Planned start Aug 2024; status: authorised.
02
Drugs
dostarlimabcholecalciferoloxaliplatinfolinic acidirinotecan
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PDAC)
Beyond the preview
Go deeper on 2023-510004-49-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510004-49-00.